Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023
LONDON and SALT LAKE CITY, June 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled...
Medicaid
Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
71% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200...
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double...
BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study
SUNNYVALE, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the treatment...
ReWalk Robotics Reports First Quarter 2023 Financial Results
On-Track Start to Fiscal Year with Progress in Advancing Reimbursement Coverage for Medicare Beneficiaries MARLBOROUGH, Mass. BERLIN and YOKNEAM ILLIT, Israel,...
Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022 CAPLYTA Q1 2023...
Horizon Healthcare Services Selects Solera Health’s Value-Based Condition Management Platform to Streamline Digital Care Delivery
Solera’s technology platform enables payers and employers to offer members seamless access to digital and community-based solutions to manage their...
Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
Availability: OLPRUVA™ drug in channel now anticipated in mid-June 2023 Awareness: 70% of metabolic treatment providers surveyed by Acer at...
Final Sanction Removed at InnovAge Sacramento PACE Center Enabling New Participant Enrollment
DENVER, May 01, 2023 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare...
TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
First quarter 2023 BRIUMVI net sales of $7.8 million Over 400 BRIUMVI prescriptions in the first partial quarter from 165+...
CorMedix Inc. Announces Regulatory, Manufacturing and Reimbursement Updates
BERKELEY HEIGHTS, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
Inovalon Expands Revenue Cycle Data Analytics Software to Support All EDI Clearinghouses for Healthcare Providers
SaaS Solution Delivers up to 93% First-Pass Yield and Prevents Revenue Leakage While Improving Cash Flow by up to 15%BOWIE,...
PersonalRX Acquires New York-Based Pharmacy
Expands high-touch, one-on-one approach to all patients in New York including MedicaidEAST RUTHERFORD, N.J., April 19, 2023 (GLOBE NEWSWIRE) --...
Clover Health Announces Business Transformation Initiatives to Accelerate Path to Profitability
Net annualized savings from initiatives expected to be approximately $30 million beginning in 2024 FRANKLIN, Tenn., April 17, 2023 (GLOBE...
Dedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In Effect
New code is expected to advance commercialization efforts in doctors’ offices and other outpatient settingsFRAMINGHAM, Mass., April 05, 2023 (GLOBE...
Milestone Scientific Provides 2022 Year-End Business Update
ROSELAND, N.J., March 31, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery...
Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results
LONDON and SALT LAKE CITY, March 30, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled...
BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results
SUNNYVALE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the treatment...
G MEDICAL INNOVATIONS AND ADVENTHEALTH IN JOINT COLLABORATION TO PROVIDE INNOVATIVE REMOTE PATIENT MONITORING SOLUTIONS FOR ADVENTHEALTH PATIENTS IN CENTRAL FLORIDA
Rehovot, Israel, March 29, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company” or “G Medical...
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed to include patients with varied...